Form 4: Outlook Therapeutics Director, Julia Haller, Acquires Stock Options

Julia Haller, a director at Outlook Therapeutics, acquired 94,441 stock options on March 7, 2024, under the company's 2015 Equity Incentive Plan.

Summary

• On March 7, 2024, Julia Haller, a director of Outlook Therapeutics, acquired 94,441 stock options.
• The options were granted under the Issuer's 2015 Equity Incentive Plan.
• The exercise price of the stock options is $0.41.
• The options will fully vest on the earlier of March 7, 2025, or the date of the Issuer's next annual meeting of stockholders, subject to continuous service.
• The options are subject to acceleration upon a Change in Control, subject to continuous service immediately prior to such Change in Control.
• The expiration date for the options is March 7, 2034.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing the acquisition of stock options by a company director. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This filing indicates Julia Haller's acquisition of stock options in Outlook Therapeutics.

Key Dates